IP Verse

Treatment Of Fibrosis - EP3298040

The patent EP3298040 was granted to National University OF Singapore on Aug 1, 2018. The application was originally filed on Dec 16, 2016 under application number EP16822941A. The patent is currently recorded with a legal status of "Revoked".

EP3298040

NATIONAL UNIVERSITY OF SINGAPORE
Application Number
EP16822941A
Filing Date
Dec 16, 2016
Status
Revoked
Sep 9, 2025
Grant Date
Aug 1, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BAYERApr 29, 2019KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2010093976
INTERNATIONAL-SEARCH-REPORTWO0078336
INTERNATIONAL-SEARCH-REPORTWO9836061
OPPOSITIONUS2009202533
OPPOSITIONWO2018109174

Non-Patent Literature (NPL) Citations (10) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- anonymous, "Human IL -11 Antibody; Monoclonal Mouse IgG2A Clone # 22626 Catalog Number: MAB218", R&D Systems, (20180702), XP055598955
OPPOSITION- "Immunsuppression durch Antikörper", Forth W. et al, Allgemeine und spezielle Pharmakologie und Toxikologie, ELSEVIER, (20130000), pages 362 - 364, XP055598946
OPPOSITION- HENNERSDORF, M. G. et al., "Das Herz bei arterieller Hypertonie", Der Internist, (20070300), vol. 3, no. 48, pages 236 - 245, XP019481634
OPPOSITION- JOHNSTONE, N. C. et al., "Emerging roles for IL -11 signalling in cancer development and progression: Focus on breast cancer", Cytokine & Growth Factor Reviews, (20150700), vol. 25, doi:10.1016/j.cytogfr.2015.07.015, pages 489 - 498, XP029276469
OPPOSITION- WYNN, T. A., "Fibrotic disease and the Thl/Th2 paradigm", Nature Reviews, (20040801), vol. 4, no. 8, pages 583 - 594, XP009070836
OPPOSITION- TANG, W. et al., "Transforming Growth Factor-β Stimulates Interleukin-11 Transcription via Complex Activating Protein-1-dependent Pathways", The Journal of Biological Chemistry, (19980306), vol. 273, no. 10, pages 5506 - 5513, XP055472902
OPPOSITION- LEE, C. G. et al., "Endogenous IL -11 Signaling Is Essential in Th2- and IL -13-Induced Inflammation and Mucus Production .", Am J Respir Cell Mol Biol, (20080000), vol. 39, doi:10.1165/rcmb.2008-0053OC, pages 739 - 746, XP055472906
OPPOSITION- TANG, W. et al., "Targeted Expression of IL -11 in the Murine Airway Causes Lymphocytic Inflammation", Bronchial Remodeling, and Airways Obstruction. The Journal ofClinical Investigation, (19960000), vol. 98, no. 12, doi:10.1172/JCI119113, pages 2845 - 2853, XP002989480
OPPOSITION- FRIEDLANDER, M., "Fibrosis and diseases ofthe eye", Journal of Clinical Investigation, (20070301), vol. 117, no. 3, pages 576 - 586, XP008114654
OPPOSITION- CHEN, Q. et al., "IL -11 Receptor alpha in the Pathogenesis of IL -13 Induced Inflammation and Remodeling.", J. Immunol., (20050000), vol. 174, doi:10.4049/jimmunol.174.4.2305, pages 2305 - 2313, XP055479849

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents